LDS/Medical Tests/Nuclear Matrix Proteins 22 (NMP22), Urine

Nuclear Matrix Proteins 22 (NMP22), Urine

The Nuclear Matrix is the name given to describe the internal structure of the cell nucleus (the part of the cell which holds the cell DNA and controls the activity of the cell) and the proteins associated with it. The NMPs leak into the blood stream, body fluids, and urine as the cells die. Different Nuclear Matrix Proteins (NMPs) have been identified to be associated with many different types of cells within the body. Additionally, the NMPs will change if a cell becomes cancerous. These changes in the NMPs allow the NMPs to be used as a biomarker for certain cancers. These cancers include bladder, kidney (renal) pelvis, prostate, breast and colon cancer.

NMP22 is closely associated with bladder cancer. Since NMP22 is tested using urine, it is a non-invasive way for a physician to screen for and monitor the progress of bladder cancer. When used in conjunction with cytologic examination (reviewing the structure of cells under the microscope) of urine, bladder cancer can be identified at earlier stages. Tissue for the diagnosis of bladder cancer is provided by cystoscopy, in which a scope is used to view the internal structure of the bladder and take a tissue biopsy.

There are several assays used for detection of NMP22 including ELISA, immunoassay, and lateral flow immunochromatographic strip assay. The most common used test is A Rapid Test for the Qualitative Detection of NMP22 Nuclear Matrix Protein in Human Urine is the NMP22™ BladderChek™ from Abbott Laboratoies, which is FDA approved test as waived (POC) test. The NMP22™ BladderChek™ Test is an in vitro immunoassay intended for the qualitative detection of the nuclear mitotic apparatus protein (NuMA), which is an abundant component of the nuclear matrix proteins, in urine of persons with risk factors or symptoms of bladder cancer or with a history of bladder cancer.

Bladder cancer (BC) becomes common with age and is more common in men than women. In the United States, bladder cancer is the 6th most common cancer with estimated new cases and deaths in 2022. Bladder cancer is the tenth leading cause of cancer death in the US. Bladder cancers are usually classified into groups based on the extent of cancer and progression: non-muscle-invasive BC and muscle-invasive BC. The earlier bladder cancer is diagnosed, the better chance a person has of surviving five (5) years after being diagnosed. The 5-year survival rates for bladder cancer patients diagnosed with localized stage and in situ alone stage are 69.6% and 96.0%, respectively.

  • As an aid in the diagnose of bladder cancer
  • An aid in monitoring bladder cancer patients in conjunction with standard diagnostic procedures

Nuclear Matrix Protein is involved in DNA replication. NMP22 is increased in patients with bladder carcinomas. NMP22 appears to be more sensitive and specific for low-grade bladder cancers than urine cytology alone.

False elevations may occur in patients with benign urinary conditions, urinary tract infection, interstitial cystitis, kidney cancer, immediately after extreme exercise in otherwise normal patients, in patients undergoing systemic chemotherapy, in patients who have undergone total cystectomy, or patients with tissue damage as the result of an invasive procedure, cystoscopy, or urinary tract catheterization.

Method Result / Reference
ELISA or Immunoassay 10 U/mL (< 10 kU/L)
Lateral flow immunochromatographic Negative
Enzyme Immunoassay, ELISA, lateral flow immunochromatographic.

Voided urine collected between midnight and noon. Must be stabilized immediately using NMP22 urine collection kit. Stabilized sample can remain at room temperature for 96 hours before centrifugation; for longer periods, store at 2-8°C. Processed samples are stable up to 1 week at 2-8°C.

For longer periods, store frozen, at -20°C for up to 8 weeks, or -80°C for longer periods.

Urine analysis, Urine Culture, UroVysion™ FISH, Bladder Tumor Associated Antigen, PSA (total), Ki-67 and p53 Tissue Assay, p21 (Waf1/Cip 1), p16,, Cytokeratin 5,6 (CK 5,6) by Immunohistochemistry.

3-7 days.

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login